IP Library Granted Patent US 6,887,999
Granted Patent B1
US 6,887,999 · App. 10/851,527 · Granted May 3, 2005

Preparation of dihydrocodeine from codeine

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,887,999
App. No.
10/851,527
Granted
May 3, 2005
Kind
B1
Abstract

A process for the preparation of dihydrocodeine by hydrogenating codeine or a salt thereof in aqueous solution in the presence of a catalytic metal and deactivating agent that decreases impurities formation.

Claims (23)

1. A process for the production of dihydrocodeine, which comprises reacting codeine or a salt thereof in an aqueous solution with hydrogen in the presence of

(i) at least one catalytic metal selected from group VIII of the Periodic Table of Elements; and

(ii) at least one deactivating agent that decreases impurities formation.

2. The process of claim 1 , wherein the catalytic metal is selected from the group consisting of nickel, palladium, rhodium, ruthenium, platinum, and combinations thereof.

3. The process of claim 1 , wherein deactivating agent is selected from the group consisting of an inorganic base, organic nitrogenous base, platinum and combinations thereof.

4. The process of claim 3 , wherein platinum is used as both the catalytic metal and deactivating agent.

5. The process of claim 3 , wherein the inorganic base is selected from the group consisting of ammonium hydroxide, lithium hydroxide, potassium hydroxide, sodium hydroxide, cesium hydroxide, ammonium bicarbonate, lithium carbonate, potassium carbonate, potassium phosphate, sodium carbonate, sodium phosphate, cesium carbonate and combinations thereof.

6. The process of claim 3 , wherein the organic nitrogenous base is selected from the group consisting of codeine, dihydrocodeine and combinations thereof.

7. The process of claim 3 , wherein organic base or a combination of organic base and inorganic base is present in amounts sufficient to maintain pH of the aqueous solution from about 5 to about 11.

8. The process of claim 3 , wherein the inorganic base is present in amounts sufficient to maintain pH of the aqueous solution from about 5 to about 10.

9. The process of claim 3 , wherein the inorganic base, organic base or a combination thereof is present in amounts sufficient to maintain pH of the aqueous solution from about 5 to about 9.

10. The process of claim 9 , wherein the inorganic base, organic base or a combination thereof is present in the amounts sufficient to maintain pH of the aqueous solution from about 6 to about 8.

11. A process for the production of dihydrocodeine, which comprises reacting codeine or a salt thereof in an aqueous solution with hydrogen in the presence of

(i) at least one a catalytic metal selected from group VIII of the Periodic Table of Elements; and

(ii) at least one inorganic base that decreases impurities formation.

12. The process of claim 11 , wherein the inorganic base comprises sodium hydroxide.

13. The process of claim 11 , wherein the inorganic base is present in amounts sufficient to maintain pH of the aqueous solution from about 5 to about 10.

14. A process for the production of dihydrocodeine, which comprises reacting codeine or a salt thereof in an aqueous solution with hydrogen in the presence of

(i) at least one catalytic metal selected from the group consisting of nickel, palladium, rhodium, ruthenium, platinum; and

(ii) at least one base that decreases impurities formation.

15. The process of claim 14 , wherein the base comprises an inorganic base.

16. The process of claim 15 , wherein the inorganic base comprises sodium hydroxide.

17. The process of claim 15 , wherein the inorganic base is present in amounts sufficient to maintain pH of the aqueous solution from about 5 to about 10.

Assignments (11)
SECURITY INTEREST Recorded Jul 2, 2019
From: ACURA PHARMACEUTICALS, INC.
To: SCHUTTE, JOHN
Reel/Frame 049649/0950 →
SECURITY INTEREST Recorded Jul 2, 2019
From: SCHUTTE, JOHN
To: ABUSE DETERRENT PHARMACEUTICALS, LLC
Reel/Frame 049650/0104 →
RELEASE OF SECURITY INTEREST Recorded Oct 11, 2018
From: OXFORD FINANCE LLC
To: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICALS TECHNOLOGIES, INC.
Reel/Frame 047140/0800 →
SECURITY INTEREST Recorded Mar 17, 2017
From: ACURA PHARMACEUTICALS, INC.; ACURA PHARMACEUTICAL TECHNOLOGIES, INC.
To: OXFORD FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 041623/0740 →
CHANGE OF NAME Recorded Jun 8, 2011
From: HALSEY DRUG CO, INC.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 026408/0220 →
RELEASE OF SECURITY INTEREST Recorded Oct 10, 2007
From: GALEN PARTNERS III, L.P.
To: ACURA PHARMACEUTICALS, INC.
Reel/Frame 019930/0568 →
SECURITY AGREEMENT Recorded Jan 31, 2006
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 017097/0150 →
SECURITY AGREEMENT Recorded Nov 11, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016769/0109 →
SECURITY INTEREST Recorded Sep 19, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016814/0160 →
SECURITY INTEREST Recorded Jun 22, 2005
From: ACURA PHARMACEUTICALS, INC.
To: GALEN PARTNERS III, L.P.
Reel/Frame 016408/0558 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 29, 2004
From: LIKHOTVORIK, IGOR
To: HALSEY DRUG COMPANY, INC.
Reel/Frame 014800/0227 →